Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
RGEN 
Repligen Corporation (RGEN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: RGEN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $190.33
1 Year Target Price $190.33
| 10 | Strong Buy |
| 4 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -13.33% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.39B USD | Price to earnings Ratio 8341 | 1Y Target Price 190.33 |
Price to earnings Ratio 8341 | 1Y Target Price 190.33 | ||
Volume (30-day avg) 19 | Beta 1.12 | 52 Weeks Range 102.97 - 182.52 | Updated Date 01/9/2026 |
52 Weeks Range 102.97 - 182.52 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.02 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 0.25% | Operating Margin (TTM) 6.71% |
Management Effectiveness
Return on Assets (TTM) 1.3% | Return on Equity (TTM) 0.09% |
Valuation
Trailing PE 8341 | Forward PE 89.29 | Enterprise Value 9308026448 | Price to Sales(TTM) 13.27 |
Enterprise Value 9308026448 | Price to Sales(TTM) 13.27 | ||
Enterprise Value to Revenue 13.15 | Enterprise Value to EBITDA 76.92 | Shares Outstanding 56290749 | Shares Floating 52682512 |
Shares Outstanding 56290749 | Shares Floating 52682512 | ||
Percent Insiders 6.33 | Percent Institutions 110.85 |
Upturn AI SWOT
Repligen Corporation
Company Overview
History and Background
Repligen Corporation was founded in 1981. It has evolved from a diversified life sciences company into a leading developer, manufacturer, and supplier of high-performance products and services for the biopharmaceutical industry. Key milestones include strategic acquisitions and divestitures to focus on its core bioprocessing business.
Core Business Areas
- Filtration: Repligen provides advanced filtration technologies for biopharmaceutical manufacturing, including single-use filtration systems and chromatography solutions used in the purification of biologics.
- Protein A Ligands: The company develops and manufactures Protein A ligands, critical components in the purification of monoclonal antibodies and other recombinant proteins. These ligands are essential for high-efficiency downstream processing.
- Process Analytics: Repligen offers a portfolio of process analytics tools and sensors that enable real-time monitoring and control of bioprocesses, improving efficiency and product quality.
- Aseptic Fluid Transfer: This segment includes single-use solutions for fluid transfer in biopharmaceutical manufacturing, ensuring sterility and reducing contamination risks during production.
Leadership and Structure
Repligen is led by a seasoned management team with extensive experience in the biopharmaceutical and life sciences industries. The company operates with a functional organizational structure, with dedicated teams for research and development, manufacturing, sales, and marketing, all focused on serving the bioprocessing market.
Top Products and Market Share
Key Offerings
- Opusu00ae Chromatography: A flagship product line offering single-use chromatography solutions for the purification of biologics. Competitors include MilliporeSigma, Sartorius, and Cytiva. Specific market share data for individual products is proprietary, but Repligen holds a significant share in the single-use chromatography market.
- XCellu00ae ATF Systems: An integrated tangential flow filtration (TFF) system for cell culture and downstream processing. Competitors include Sartorius and Cytiva. Repligen is a leading provider in the cell retention and perfusion market.
- ProSepu00ae-vA and ProSep-dA Ligands: High-performance Protein A affinity ligands used for antibody purification. Competitors include Cytiva and MilliporeSigma. These ligands are critical components in antibody manufacturing, and Repligen is a key supplier.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by significant growth driven by increasing demand for biologics, personalized medicine, and a robust pipeline of novel therapies. The bioprocessing segment, in particular, is experiencing strong tailwinds due to the need for efficient, scalable, and flexible manufacturing solutions, including a shift towards single-use technologies.
Positioning
Repligen is well-positioned as a critical supplier to the biopharmaceutical industry, offering specialized, high-performance products that enhance the efficiency and quality of biologics manufacturing. Its focus on innovation, strategic acquisitions, and a strong customer base provides a competitive advantage.
Total Addressable Market (TAM)
The global bioprocessing market is substantial and growing, estimated to be tens of billions of dollars. Repligen's TAM is within this broader market, focusing on consumables and equipment for upstream and downstream processing of biologics. Repligen aims to capture a significant portion of this market by providing essential solutions to leading biopharmaceutical companies.
Upturn SWOT Analysis
Strengths
- Strong product portfolio in bioprocessing consumables and equipment.
- Leading market positions in key segments like Protein A ligands and single-use chromatography.
- Acquisition strategy has successfully integrated complementary technologies and expanded market reach.
- Long-standing relationships with major biopharmaceutical companies.
- Focus on innovation and new product development.
Weaknesses
- Dependence on a relatively concentrated customer base.
- Potential for supply chain disruptions impacting raw material availability or product delivery.
- Integration risks associated with ongoing acquisitions.
- Competition from larger, more diversified players in the life sciences industry.
Opportunities
- Continued growth in the biologics market and demand for advanced therapies.
- Expansion into emerging markets and new therapeutic areas.
- Development of next-generation bioprocessing technologies.
- Increasing adoption of single-use manufacturing technologies.
- Further strategic acquisitions to broaden product offerings and market access.
Threats
- Intensifying competition and potential price erosion.
- Regulatory changes impacting biopharmaceutical manufacturing.
- Macroeconomic downturns affecting R&D spending by biopharmaceutical companies.
- Technological obsolescence if innovation lags.
- Potential litigation or intellectual property disputes.
Competitors and Market Share
Key Competitors
- Cytiva
- Sartorius AG
- Danaher Corporation (through its subsidiaries like Pall Corporation and Cytiva)
- Thermo Fisher Scientific
- MilliporeSigma (Merck KGaA)
Competitive Landscape
Repligen competes in a dynamic and consolidated market. Its competitive advantages lie in its specialized focus on bioprocessing, its proprietary technologies (like Protein A ligands and XCell ATF), and its reputation for quality and innovation. However, it faces competition from larger, more diversified companies with broader product portfolios and greater R&D resources.
Major Acquisitions
Kalo Bio
- Year: 2022
- Acquisition Price (USD millions): 477
- Strategic Rationale: Acquisition of Kalo Bio expanded Repligen's capabilities in gene therapy and novel biologics development, adding complementary technologies and market potential.
Gene & Cell Therapy
- Year: 2021
- Acquisition Price (USD millions): 180
- Strategic Rationale: This acquisition bolstered Repligen's offerings in the rapidly growing gene and cell therapy market, enhancing its portfolio of critical process solutions.
Growth Trajectory and Initiatives
Historical Growth: Repligen has experienced significant historical growth, fueled by a combination of organic expansion within its established product lines and the successful integration of acquired businesses. Its focus on the expanding bioprocessing market has been a key driver.
Future Projections: Analyst consensus generally projects continued strong revenue and earnings growth for Repligen, driven by ongoing demand for biologics manufacturing solutions and the company's strategic pipeline. Projections typically indicate double-digit growth rates for the foreseeable future.
Recent Initiatives: Recent initiatives include strategic acquisitions to expand its portfolio in critical bioprocessing areas, investments in manufacturing capacity to meet growing demand, and the continued development of innovative new products to address evolving customer needs.
Summary
Repligen Corporation is a strong player in the biopharmaceutical manufacturing market, excelling in specialized areas like filtration and Protein A ligands. Its strategic acquisitions have effectively expanded its product offerings and market reach. The company benefits from the robust growth of the biologics sector. However, it must remain vigilant against intense competition and potential supply chain vulnerabilities.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Repligen Corporation Investor Relations
- Financial news outlets (e.g., Bloomberg, Reuters, Wall Street Journal)
- Industry analysis reports
- Company SEC filings (10-K, 10-Q)
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. Market share data and financial figures are estimates and may vary. Investors should conduct their own due diligence and consult with a qualified financial advisor before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Repligen Corporation
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 1990-03-26 | President, CEO & Director Mr. Olivier Loeillot | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 1778 | Website https://www.repligen.com |
Full time employees 1778 | Website https://www.repligen.com | ||
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.